An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and thymosin beta-4. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may help treat antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn steady interest from users seeking alternatives to traditional drugs. Scientists say peptide treatments could alter approaches to stubborn infections, though concerns about safety persist. The committee's endorsement of six peptides paves the way for more broad prescribing, even as watchdogs warn of short-term evidence. Industry analysts note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on certain peptide candidates.